Last reviewed · How we verify
Adebrelimab combined with chemotherapy
Immune checkpoint inhibitor
Immune checkpoint inhibitor Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | Adebrelimab combined with chemotherapy |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Adebrelimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to recognize and attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma (PHASE2)
- Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma. (PHASE2)
- A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (PHASE2, PHASE3)
- Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC (PHASE2)
- Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. (PHASE2)
- Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study (PHASE2)
- Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: